ICM
NVS icon

Islay Capital Management’s Novartis NVS Stock Holding History

Islay Capital Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250
Closed -$24K – 309
2020
Q4 		$24K Hold
250
– – 0.02% 208
2020
Q3 		$22K Hold
250
– – 0.02% 210
2020
Q2 		$22K Hold
250
– – 0.03% 195
2020
Q1 		$21K Hold
250
– – 0.03% 190
2019
Q4 		$24K Buy
+250
New +$22.4K 0.02% 200

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Islay Capital Management's NVS Position: Q1 2021 in Review

Islay Capital Management sold out of Novartis (NVS) in Q1 2021, closing a stake of 250 shares — an estimated $24K sold.

Islay Capital Management first reported a position in NVS in Q4 2019 and held it in 5 quarters. The position peaked at $24K in Q4 2020. 1,135 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

  • Islay Capital Management reported no remaining Novartis position as of Q1 2021 after selling out during the quarter.
  • Islay Capital Management sold 250 Novartis shares in Q1 2021, an estimated $24K.
  • Islay Capital Management first reported a position in Novartis in Q4 2019 and held it in 5 quarters.
  • Islay Capital Management's Novartis position peaked at $24K in Q4 2020.
  • 1,135 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on Islay Capital Management's 13F filing for Q1 2021, filed 11 May 2021.